Medicine and Dentistry
Human Immunodeficiency Virus
77%
Cryptococcal Meningitis
58%
Therapeutic Procedure
43%
Antigen
37%
Cost-Effectiveness Analysis
35%
Health Care Cost
30%
Person
27%
Screening
26%
Cerebrospinal Fluid
25%
Combination Therapy
23%
Meningitis
22%
COVID-19
20%
Fluconazole
20%
Diagnosis
19%
Amphotericin
19%
Patient
17%
Mortality
17%
Disease
17%
Antiretroviral Therapy
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Infection
16%
Drug Megadose
16%
Outpatient
15%
Enalapril Maleate
15%
Clinical Trial
14%
Analysis
14%
Tuberculous Meningitis
11%
Amphotericin B Lipid Complex
11%
Diagnostics
11%
Survival
11%
Health
9%
Tuberculosis
9%
Cells
8%
Death
8%
Adult
8%
Culture
7%
Monotherapy
7%
Laboratory
7%
Randomized Clinical Trial
6%
Infectious Disease
6%
Symptom
6%
Plasma
5%
Systematic Review
5%
Fecal Microbiota Transplantation
5%
Quality Adjusted Life Year
5%
Obstetric Delivery
5%
Virus Infection
5%
Monitoring
5%
Cohort Analysis
5%
Hospital
5%
Immunology and Microbiology
Meningitis
100%
Human Immunodeficiency Virus
72%
Antigen
65%
Cerebrospinal Fluid
33%
Mortality
24%
Hydroxychloroquine
24%
COVID-19
24%
Flow
22%
Screening
18%
Cells
17%
CD4
13%
Prevalence
13%
CD4 Lymphocyte Count
12%
Titer
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Survival
9%
Tuberculous Meningitis
9%
Sample
8%
Blood Plasma
7%
Pregnancy
7%
Mental Health
7%
Cytokine
6%
Immune Response
6%
Internet
5%
Cytomegalovirus
5%
Cryptococcus neoformans
5%
Disease Burden
5%
Puerperium
5%
Chloroquine
5%
Incidence
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cryptococcal Meningitis
50%
HIV
45%
Antigen
38%
Fluconazole
38%
Hydroxychloroquine
27%
Meningitis
24%
Diseases
23%
Amphotericin
21%
Enalapril Maleate
21%
Coronavirinae
20%
Infection
16%
Survival
15%
Clinical Trial
14%
Randomized Clinical Trial
12%
Mortality
11%
Randomized Controlled Trial
11%
Amphotericin B Lipid Complex
11%
SARS Coronavirus
10%
Cluster Randomized Trial
9%
Tuberculous Meningitis
9%
Monotherapy
8%
Death
7%
Filobasidiella
7%
Placebo
6%
Cryptococcosis
6%
Sertraline
6%
Adverse Event
6%
Amphotericin B
6%
Cohort Study
5%
Flucytosine
5%
Case Report
5%